The leading industry resource for royalty-rate benchmarking, built on 1,635 real-world pharmaceutical and biotechnology licensing deals.
Royalty Rates in Pharmaceutical and Biotechnology Licensing Deals 2015-2026 is a trusted benchmarking resource used by life science companies, advisers and transaction teams to understand and compare royalty economics across real-world licensing agreements.
Updated regularly and relied on by customers year after year, the report provides comprehensive intelligence on 1,635 royalty-bearing licensing transactions, enabling users to investigate how royalty terms are structured across the pharmaceutical and biotechnology industry.
Royalty rates are among the most commercially important — and frequently negotiated — elements of a licensing agreement. Yet an individual royalty percentage has limited meaning when considered in isolation.
Development stage, therapeutic area, technology, exclusivity, territory, development responsibilities, upfront payments, milestones and the wider economics of the transaction can all influence the royalty structure agreed between the parties.
The report brings these factors together, allowing users to move beyond broad industry averages and identify comparable licensing transactions that more closely reflect the asset, technology and deal structure they are evaluating.
Rather than simply providing a collection of royalty percentages, the report combines royalty-rate intelligence with detailed transaction context, financial terms, company activity, comprehensive deal directories and access to publicly available licensing agreements and royalty clauses where available.
It provides a practical benchmarking and decision-support resource for business development, licensing, valuation, finance, legal, corporate strategy and senior management teams involved in structuring, evaluating or negotiating life science licensing transactions.
A royalty rate agreed for an early-stage technology platform may have very different economics from one associated with a clinical-stage or marketed product. Similarly, worldwide exclusivity, regional rights, development obligations and the balance between upfront, milestone and downstream payments can materially affect the royalty structure.
The report provides the transaction context needed to interpret these differences.
This helps avoid treating stage-based averages as standalone valuation measures and provides the transaction-level context required for more meaningful comparison.
These contracts can provide considerably more detail than press releases or headline financial disclosures alone.
Identify comparable transactions, benchmark royalty structures and prepare evidence for licensing discussions and negotiations.
Valuation and Finance teams
Use real transaction evidence to test royalty assumptions within asset valuations, forecasts and financial models.
Corporate Development and Strategy teams
Understand licensing economics and how companies are structuring royalty-bearing transactions across different assets and technologies.
Legal and Transaction teams
Review real-world royalty clauses and associated licensing provisions to support drafting and negotiation.
Technology Transfer and Commercialization teams
Investigate comparable royalty-bearing transactions when licensing intellectual property, technologies and development programs.
Senior Management and Investment Committees
Use comparable transaction evidence to assess proposed licensing economics and support internal transaction review.
Consultants, Advisers and Investors
Access structured royalty-rate and transaction intelligence for valuation, due diligence and transaction analysis.
Licensing markets evolve, new technologies emerge, development strategies change and transaction structures continue to develop. The relevance of comparable deals therefore changes over time.
The analyst regularly updates the underlying royalty intelligence so users can work from a current body of disclosed licensing evidence rather than relying on static historical benchmarks.
For organizations involved in repeated licensing activity, this makes the report a continuing reference resource for deal preparation, internal benchmarking, valuation support and negotiation.
Its value lies not simply in the number of royalty rates captured, but in the ability to understand each rate within the wider commercial and contractual context of the transaction.
The briefing applies the underlying royalty-rate and licensing intelligence to the customer's own asset, technology, development program or transaction objectives.
Depending on requirements, this can include relevant comparable transactions, development-stage benchmarking, royalty-rate analysis, wider deal economics, prospective partners, contract insights and other intelligence selected specifically for the client's situation.
This provides a focused layer of analysis alongside the broader market-wide evidence contained within the report.
Royalty Rates in Pharmaceutical and Biotechnology Licensing Deals 2015-2026 is a trusted benchmarking resource used by life science companies, advisers and transaction teams to understand and compare royalty economics across real-world licensing agreements.
Updated regularly and relied on by customers year after year, the report provides comprehensive intelligence on 1,635 royalty-bearing licensing transactions, enabling users to investigate how royalty terms are structured across the pharmaceutical and biotechnology industry.
Royalty rates are among the most commercially important — and frequently negotiated — elements of a licensing agreement. Yet an individual royalty percentage has limited meaning when considered in isolation.
Development stage, therapeutic area, technology, exclusivity, territory, development responsibilities, upfront payments, milestones and the wider economics of the transaction can all influence the royalty structure agreed between the parties.
The report brings these factors together, allowing users to move beyond broad industry averages and identify comparable licensing transactions that more closely reflect the asset, technology and deal structure they are evaluating.
Rather than simply providing a collection of royalty percentages, the report combines royalty-rate intelligence with detailed transaction context, financial terms, company activity, comprehensive deal directories and access to publicly available licensing agreements and royalty clauses where available.
It provides a practical benchmarking and decision-support resource for business development, licensing, valuation, finance, legal, corporate strategy and senior management teams involved in structuring, evaluating or negotiating life science licensing transactions.
Benchmark royalty rates in context
The report enables users to investigate royalty rates according to factors including:
- Stage of development at signing
- Therapeutic area
- Technology type
- Company
- Licensing structure
- Exclusivity
- Territorial rights
- Upfront payments
- Development, regulatory and commercial milestones
- Wider transaction economics
A royalty rate agreed for an early-stage technology platform may have very different economics from one associated with a clinical-stage or marketed product. Similarly, worldwide exclusivity, regional rights, development obligations and the balance between upfront, milestone and downstream payments can materially affect the royalty structure.
The report provides the transaction context needed to interpret these differences.
Understand how royalty structures are built
Royalty provisions can take many forms.Depending on the transaction and available disclosure, users can investigate:
- Fixed royalty rates
- Royalty ranges
- Tiered royalty structures
- Escalating royalties
- Royalty reductions
- Sales thresholds
- Royalty duration
- Territory-specific royalties
- Exclusivity-related provisions
- Sublicensing economics
- Revenue-sharing arrangements
- Related milestone and payment structures
Compare royalty rates by development stage
Development stage can be an important factor when assessing comparable licensing economics.The report enables users to investigate royalty-bearing transactions involving:
- Discovery-stage opportunities
- Preclinical assets
- Clinical-stage products
- Late-stage programs
- Marketed products
This helps avoid treating stage-based averages as standalone valuation measures and provides the transaction-level context required for more meaningful comparison.
Benchmark the wider economics of licensing deals
Royalty rates form only one part of the overall economics of a licensing agreement.The report enables users to examine royalties alongside disclosed:
- Upfront payments
- Development milestones
- Regulatory milestones
- Commercial milestones
- Research and development funding
- Equity investment
- Headline deal value
- Other financial consideration
Identify relevant comparable licensing transactions
One of the most important challenges in royalty benchmarking is finding transactions that are genuinely comparable.The report enables users to investigate licensing deals according to:
- Company
- Therapy area
- Technology
- Development stage
- Financial structure
- Territory
- Exclusivity
- Royalty structure
Identify companies actively agreeing and disclosing royalty terms
The report identifies companies involved in royalty-bearing licensing transactions and highlights organizations that have repeatedly disclosed royalty terms.This can help users investigate:
- Previous licensing behavior
- Royalty structures used by individual companies
- Relevant precedent transactions
- Companies active within particular therapy or technology areas
- Potential counterparties with an established history of licensing activity
Learn from real-world licensing agreements and royalty clauses
Where publicly available, the report provides access to underlying licensing agreements associated with selected transactions.These contracts can provide considerably more detail than press releases or headline financial disclosures alone.
Users can examine how companies have documented areas including:
- Royalty percentages and ranges
- Tiered royalty structures
- Sales thresholds
- Royalty escalation and reduction mechanisms
- Royalty duration
- Exclusivity
- Territory
- Sublicensing provisions
- Milestones
- Other related commercial terms
Comprehensive royalty-rate deal directory
The report includes comprehensive directories covering 1,635 royalty-bearing pharmaceutical and biotechnology licensing transactions from 2015 to 2026.Deals can be investigated by:
- Company
- Therapy area
- Stage of development at signing
- Technology type
Who should use this report?
Business Development and Licensing teamsIdentify comparable transactions, benchmark royalty structures and prepare evidence for licensing discussions and negotiations.
Valuation and Finance teams
Use real transaction evidence to test royalty assumptions within asset valuations, forecasts and financial models.
Corporate Development and Strategy teams
Understand licensing economics and how companies are structuring royalty-bearing transactions across different assets and technologies.
Legal and Transaction teams
Review real-world royalty clauses and associated licensing provisions to support drafting and negotiation.
Technology Transfer and Commercialization teams
Investigate comparable royalty-bearing transactions when licensing intellectual property, technologies and development programs.
Senior Management and Investment Committees
Use comparable transaction evidence to assess proposed licensing economics and support internal transaction review.
Consultants, Advisers and Investors
Access structured royalty-rate and transaction intelligence for valuation, due diligence and transaction analysis.
Why companies return to this report year after year
Royalty benchmarking is not a one-off exercise.Licensing markets evolve, new technologies emerge, development strategies change and transaction structures continue to develop. The relevance of comparable deals therefore changes over time.
The analyst regularly updates the underlying royalty intelligence so users can work from a current body of disclosed licensing evidence rather than relying on static historical benchmarks.
For organizations involved in repeated licensing activity, this makes the report a continuing reference resource for deal preparation, internal benchmarking, valuation support and negotiation.
Its value lies not simply in the number of royalty rates captured, but in the ability to understand each rate within the wider commercial and contractual context of the transaction.
Turn market-wide royalty intelligence into transaction-specific insight
For qualifying customers, the analyst can also provide a Customized Executive Partnering Briefing alongside the report.The briefing applies the underlying royalty-rate and licensing intelligence to the customer's own asset, technology, development program or transaction objectives.
Depending on requirements, this can include relevant comparable transactions, development-stage benchmarking, royalty-rate analysis, wider deal economics, prospective partners, contract insights and other intelligence selected specifically for the client's situation.
This provides a focused layer of analysis alongside the broader market-wide evidence contained within the report.
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - An overview of pharmaceutical and biotechnology royalty rates
Chapter 3 - The royalty clause in pharmaceutical and biotechnology deals
Chapter 4 - Companies actively disclosing royalty rates
Chapter 5 - Royalty rate contract directory
Deal Directory
Royalty rate references
Table of figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 2seventy bio
- 3a-diagnostics
- 3B Pharmaceuticals
- 3D Medicines
- 3SBio
- 4D Molecular Therapeutics
- 4SC
- 9 Meters Biopharma
- 23andMe
- Aadi Bioscience
- Abbisko Therapeutics
- Abbvie
- AbCellera Biologics
- Abeona Therapeutics
- Abex Pharmaceutica
- ABL Bio
- Ablynx
- ABVC BioPharma
- ABX
- ACADIA Pharmaceuticals
- Acceleron Pharma
- Accent Therapeutics
- Accord Healthcare
- Accro Bioscience
- Accure Therapeutics
- Acelrx Pharmaceuticals
- Acer Therapeutics
- Acerus
- AC Immune
- Aclaris Therapeutics
- Acorda Therapeutics
- Acrotech Biopharma
- Actinium Pharmaceuticals
- Acuitas Therapeutics
- Acumen Pharmaceuticals
- Acura Pharmaceuticals
- Adamis Pharmaceuticals
- Adaptimmune
- AdaptVac
- Adcendo
- ADC Therapeutics
- ADEL
- Adial Pharmaceuticals
- Adimab
- Aditx Therapeutics
- Adlai Nortye
- Adneuris Therapeutics
- Adocia
- Adovate
- Aduro BioTech
- Advaccine Biotechnology
- Advanced Dosage Forms
- Advanz Pharma
- Advaxis
- Aegerion Pharmaceutical
- Aeglea BioTherapeutics
- Aelis Pharma
- Aerami Therapeutics
- Aerie Pharmaceuticals
- Aeromics
- Aerpio Pharmaceuticals
- AEterna Zentaris
- Aevi Genomic Medicine
- Aexon Labs
- Affibody
- Affimed Therapeutics
- AFFiRiS
- AFT Pharmaceuticals
- Agenus Bio
- Agios Pharmaceuticals
- AgNovos Healthcare
- Aguettant
- AiBtl BioPharma
- Aimmune Therapeutics
- AirNexis Therapeutics
- Aitia
- AIT Therapeutics
- Akamis Bio
- Akcea Therapeutics
- Akebia Therapeutics
- Akeso Biopharma
- Alaunos Therapeutics
- Albireo
- Alder Biopharmaceuticals
- Alector
- Alexion Pharmaceuticals
- Alfasigma
- Aligos Therapeutics
- ALK-Abello
- Alkem Laboratories
- Allecra Therapeutics
- Allergan
- Allist Pharma
- Allogene Therapeutics
- Almirall
- Alnylam Pharmaceuticals
- Alora Pharmaceuticals
- Alpha Biopharma
- Alphamab Biopharmaceuticals
- Alphamab Oncology
- Alpine Immune Sciences
- Altamira Pharma
- Alteogen
- Alternavida
- Altesa Biosciences
- Altum Pharmaceuticals
- Alumis
- Aluztra Bio
- Alvogen
- AlzeCure Pharma
- Amag Pharmaceuticals
- Amarantus BioSciences
- Amarin
- Ambrx
- Amgen
- Amherst Pharmaceuticals
- Amicus Therapeutics
- AMMTeK
- Amneal Pharmaceuticals
- Amphista Therapeutics
- Amplyx Pharmaceuticals
- Amryt Pharma
- Amylyx Pharmaceuticals
- AnaptysBio
- AnGes MG
- Angion Biomedica
- AnHeart Therapeutics
- Anima Biotech
- Anivive Lifesciences
- AnnJi Pharmaceutical
- Antares Pharma
- Antares Therapeutics
- Antengene
- Anteris Bio
- Antibe Therapeutics
- Antigen Express
- Antion Biosciences
- Apellis Pharmaceuticals
- Apic Bio
- ApolloBio
- Apollo Therapeutics
- Applied Therapeutics
- AprilBio
- Aptamer Therapeutics
- Aptose Biosciences
- Aquestive Therapeutics
- Aravive Biologics
- Arbor Biotechnologies
- Arbormentis
- Arbutus
- ARCA Biopharma
- Arcellx
- Arch Pharmalabs
- Arctic Vision
- Arcturus Therapeutics
- Arcus Biosciences
- Arcutis Biotherapeutics
- Ardelyx
- Arena Pharmaceuticals
- argenx
- Ariad Pharmaceuticals
- Aridis Pharmaceuticals
- Arlington Scientific
- ArQule
- Arrakis Therapeutics
- Array Biopharma
- Arrowhead Pharmaceuticals
- ARScience Biotherapeutics
- ARS Pharmaceuticals
- Artios Pharma
- Artiva Biotherapeutics
- Arvinas
- Asahi Kasei
- Ascendis Pharma
- Asceneuron
- Ascentage Pharma
- Ascletis
- Ashvattha Therapeutics
- ASKA Pharmaceuticals
- Aslan Pharma
- Aspire Health Science
- Aspire Pharma
- Assembly Biosciences
- Assistance Publique-Hôpitaux de Paris
- Astellas Pharma
- AstraZeneca
- Astria Therapeutics
- Atara Biotherapeutics
- Athenex
- Athersys
- Athira Pharma
- Atlantic Healthcare
- Atossa Therapeutics
- Atreca
- Audentes Therapeutics
- Augmenta
- AUM Biosciences
- Auransa
- Aurealis Therapeutics
- Aurigene Discovery Technologies
- Aurinia Pharmaceuticals
- Authentic Brands Group
- Autolus
- Avacta
- Avadel Pharmaceuticals
- Avalo Therapeutics
- Avata Biosciences
- Avecho Biotechnology
- Avenue Therapeutics
- AVEO Oncology
- Avero Diagnostics
- Avid Bioservices
- Avidity Biosciences
- Avivagen
- Axovant Gene Therapies
- Axsome Therapeutics
- Aytu BioPharma
- Azaya Therapeutics
- Azurity Pharmaceuticals
- Baker Brothers Investments
- BAKX Therapeutics
- Baliopharm
- Basilea Pharmaceutica
- Bausch Health Companies
- Bavarian Nordic
- Baxalta
- Bayer
- Beam Therapeutics
- BeiGene
- Beijing Defengrei Biotechnology
- Beijing InnoCare Pharma
- Beijing Mabworks Biotech
- Beijing Podconley Pharmaceutical Technology and Development
- Bellerophon Therapeutics
- Bellicum Pharmaceuticals
- Benitec Biopharma
- Benuvia Therapeutics
- BeOne Medicines
- Besins Healthcare
- Beta Bionics
- Betta Pharmaceuticals
- BetterLife Pharma
- Bharat Biotech
- BICO
- Bicycle Therapeutics
- Bio-Rad Laboratories
- Bio-Thera Solutions
- BioArctic AB
- biOasis Technologies
- BioAtla
- Biocodex
- Biocon
- BioCorRx
- BioCryst Pharmaceuticals
- Biocytogen
- BioDelivery Sciences
- Biodexa Pharmaceuticals
- Bioeq IP
- Biogen
- BioGenetics
- Biohaven Pharmaceuticals
- BioHEP Technologies
- BioInvent
- BiolineRX
- Biolojic Design
- BioMarin Pharmaceutical
- Biomerica
- Biond Biologics
- BioNexus Gene Lab
- BioNova Pharmaceuticals
- BioNovion
- BioNTech
- BioNxt Solutions
- Biopas Laboratories
- BiopharmX
- BioPhausia
- Biophytis
- Bioprocess Capital Ventures
- Bioprojet
- Biora Therapeutics
- BioSense Global
- Biosion
- Biosplice
- Biossil
- Biostem US
- BioTheryX
- Bioverativ
- Bixink Therapeutics
- Blackstone
- Blanver
- Bluebird Bio
- Blueprint Medicines
- BlueRock Therapeutics
- BMV Medica
- BNC Korea
- Boehringer Ingelheim
- Bone Therapeutics
- Boryung Pharmaceutical
- Botanix Pharmaceuticals
- Braeburn Pharmaceuticals
- Breathtec BioMedical
- BriaCell Therapeutics
- BriaPro Therapeutics
- Brickell Biotech
- BridgeBio Pharma
- Bridge Biotherapeutics
- BridGene Biosciences
- Brigham and Women's Hospital
- Brii Biosciences
- Bristol-Myers Squibb
- C4 Therapeutics
- Cabaletta Bio
- Calidi Biotherapeutics
- California Institute for Biomedical Research
- Calithera Biosciences
- Calliditas Therapeutics
- CAMP4 Therapeutics
- Camurus
- Can-Fite BioPharma
- CanAm Bioresearch
- CANbridge Pharmaceuticals
- Cancer Prevention Pharmaceuticals
- Candel Therapeutics
- Cannassure Therapeutics
- CanniMed Therapeutics
- Cann Pharmaceutical Australia
- Canntab Therapeutics
- Cannus Partners
- CanProbe
- Cantabria Pharma
- Cantargia
- Cantex Pharmaceuticals
- Capricor Therapeutics
- Capsida Biotherapeutics
- Cara Therapeutics
- Cardiff University
- Caribou Biosciences
- Carna BioSciences
- Carpegen
- CASI Pharmaceuticals
- Cassiopea
- Castle Biosciences
- Castle Creek Biosciences
- Catalyst Pharmaceuticals
- Catholic University Leuven
- CB2 Therapeutics
- CBC Group
- Cedars-Sinai Medical Center
- Celdara Medical
- Celgene
- CellAct
- Cell Cure Neurosciences
- Cellectis
- Cellenkos
- Cellerant Therapeutics
- Cellular Biomedicine
- Cellvera
- Celyad
- Cend Therapeutics
- Centessa Pharmaceuticals
- Centrexion
- Cereal Ingredients
- Cerus
- CGA 369
- cGreen
- Checkpoint Therapeutics
- Chelexa Biosciences
- Chengdu Kanghua Biological Products
- Chi-Med
- Chiesi Farmaceutici
- Chimerix
- China Oncology Focus
- Chinese University of Hong Kong
- Chinook Therapeutics
- Chong Kun Dang
- Chongqing Jingdong Pharmaceutical
- Chugai Pharmaceutical
- Cidara Therapeutics
- Cilag AG
- Cipher Pharmaceuticals
- Cipla
- Circassia
- Cirna Diagnostics
- Citius Pharmaceuticals
- City of Hope
- City Therapeutics
- Clearmind Medicine
- Clearside Biomedical
- Cleave Therapeutics
- Clementia Pharmaceuticals
- Cleveland BioLabs
- Click Therapeutics
- Climb Bio
- Clinigen
- Clovis Oncology
- CMG Pharmaceutical
- CMS Medical
- CNS Pharmaceuticals
- Coave Therapeutics
- Cocrystal Pharma
- Codex DNA
- Codexis
- Codiak BioSciences
- Coeptis Pharmaceuticals
- Coherus Biosciences
- Collegium Pharmaceuticals
- Columbia Care
- Columbia University
- Common Sense
- Compugen
- Conatus Pharmaceuticals
- ConforMIS
- Consilient Health
- Context Therapeutics
- Contineum Therapeutics
- Copernicus Therapeutics
- Corbus Pharmaceuticals
- CorMatrix Cardiovascular
- Cortice Biosciences
- CORXEL Pharmaceuticals
- Cosmofix
- Cosmo Pharmaceuticals
- COUR Pharmaceutical
- Coya Therapeutics
- Crescita Therapeutics
- Crestovo
- CRISPR Therapeutics
- Crossject
- Crosswalk Therapeutics
- CRT Pioneer Fund
- CrystalGenomics
- CSL
- CSL Behring
- CSPC Pharmaceutical Group
- CS Pharmaceuticals
- CStone Pharmaceuticals
- CTI BioPharma
- CTT Pharmaceutical
- Cue Biopharma
- Cullinan Oncology
- Cullinan Therapeutics
- Cumberland Pharmaceuticals
- Cumulus Oncology
- Curadev Pharma
- Curasight
- Curatis
- Cures Within Reach
- Curetis
- CureVac
- Curis
- Curium
- Curon Biopharmaceutical
- Currax Pharmaceuticals
- Cybin
- Cyclerion Therapeutics
- CymaBay Therapeutics
- Cyprium Therapeutics
- Cytodyn
- Cytokinetics
- CytoLynx Therapeutics
- CytomX Therapeutics
- Cytori Therapeutics
- Cytovant Sciences
- CYTOVIA Therapeutics
- CytRx
- D&D Pharmatech
- D. E. Shaw Research
- Daewoong Pharmaceutical
- Daiichi Sankyo
- Dare Bioscience
- DAS Therapeutics
- Day One Biopharmaceuticals
- DCx Biotherapeutics
- Debiopharm
- Decibel Therapeutics
- Deciphera Pharmaceuticals
- Deimos Biosciences
- DelSiTech
- Denali Therapeutics
- Department of Health and Human Services
- DepoMed
- Dermavant Sciences
- Dermelix Biotherapeutics
- Dermira
- DeuteRx
- DiaMedica
- Dianomi Therapeutics
- Dianthus Therapeutics
- Dicerna Pharmaceuticals
- Dimerix Biosciences
- Diurnal
- Dong-A ST
- Dr. Falk Pharma
- Dr. Reddy's Laboratories
- Dragonfly Therapeutics
- Dren Bio
- DRI Capital
- DRI Healthcare
- DualityBio
- Duke University
- Durect
- Dyadic International
- Dynavax Technologies
- Eagle Pharmaceuticals
- EA Pharma
- Earendil Labs
- Easton Pharmaceuticals
- Eberhard Karls University Tubingen
- Eczacibasi Pharmaceuticals
- Egalet
- Eidos Therapeutics
- Eiger BioPharmaceuticals
- EirGen Pharma
- Eirion Therapeutics
- Eisai
- Elanco
- Elektrofi
- Elencee
- Elevar Therapeutics
- Eli Lilly
- Elpiscience
- Emerald Organic Growth
- Emergent BioSolutions
- Emmaus Life Sciences
- Emory University
- Emtora Biosciences
- Enable Injections
- Enalare Therapeutics
- EndoCeutics
- Endocyte
- Endo International
- EndoLogic
- Endo Ventures
- EnGeneIC
- Engitix
- Enochian Biosciences
- Ensho Therapeutics
- Ensoma
- Entera Bio
- Enteris Biopharma
- Entrada Therapeutics
- Enumeral Biomedical
- Enveric Biosciences
- Enzymotec
- EPI Health
- Epitopea
- Epizyme
- EQRx
- Equillium
- Erasca
- Ergomed
- Esperion Therapeutics
- Eterna Therapeutics
- Ethypharm
- Eton Pharmaceuticals
- Euratom
- Eurofarma
- Evecxia
- Evelo Biosciences
- Everest Medicines
- Everest Pharma
- Eversana
- Evoke Pharma
- Evotec
- Evox Therapeutics
- Ewopharma
- Exacis Biotherapeutics
- Exact Sciences
- Exavir Therapeutics
- Exelixis
- Exeltis
- Exicure
- ExpreS2ion Biotechnologies
- Exscientia
- EyeCRO
- Eyenovia
- Eyevance
- F-Star Therapeutics
- F1 Oncology
- Famy Life Sciences
- Fate Therapeutics
- Fennec Pharmaceuticals
- Ferozsons Laboratories
- Ferrer
- Ferring Pharmaceuticals
- Fibrocell Science
- Fidelion Diagnostics
- Filament Health
- First Wave Bio
- Five Prime Therapeutics
- Flexion Therapeutics
- Foghorn Therapeutics
- Forcefield Therapeutics
- Foresee Pharmaceuticals
- FORMA Therapeutics
- Formation Bio
- Formycon
- ForSeeCon Eye Corporation
- Fortify Therapeutics
- Forty Seven
- FORUS Therapeutics
- Fosun Pharmaceutical
- Fosun Wanbang
- Fox Chase Chemical Diversity Center
- Freeline Therapeutics
- Freenome
- Frequency Therapeutics
- Fresenius Kabi Pharmaceuticals
- Fresh Tracks Therapeutics
- Frontier Biotech
- Frontier Medicines
- FSD Pharma
- FUJIFILM Cellular Dynamics
- Fulcrum Therapeutics
- Fusion Pharmaceuticals
- FutureGen Biopharm
- G1 Therapeutics
- Gaelan Medical
- Galapagos
- Galderma
- Galenica
- Galera Therapeutics
- Galmed Pharmaceuticals
- Gamida Cell
- GC Pharma
- GE Healthcare
- GEMMA Biotherapeutics
- GenEdit
- Genelux
- Genentech
- GeneQuantum Healthcare
- GeneQuine Biotherapeutics
- Generate Biomedicines
- Generex Biotechnology
- Generian Pharmaceuticals
- Genetix Biotherapeutics
- Genevant Sciences
- Genexine
- Genfit
- GenFleet Therapeutics
- Genhouse Bio
- GenKOre
- Genmab
- Genor Biopharma
- Genovis
- Genrix Bio
- Gensci
- GenScript ProBio
- Genzyme
- German Cancer Research Center
- Germfree
- Gicell
- Gilead Sciences
- Gilgamesh Pharmaceuticals
- Glaukos
- Glenmark Pharmaceuticals
- Glenmark Pharmaceuticals S.A.
- Global Blood Therapeutics
- Goldfinch Bio
- Gossamer Bio
- GO Therapeutics
- GPCR Therapeutics
- Gracell Biotechnologies
- Grail
- Gravitas Therapeutics
- Graviton Bioscience
- Gravocore
- Grifols
- Gritstone Bio
- GSK
- GT Biopharma
- Guangzhou Xiangxue Pharmaceutical
- Gurnet Point Capital
- Hai Kang Life
- Haisco Pharmaceutical
- Halo Labs
- Halozyme Therapeutics
- HanAll Pharmaceuticals
- Handa Therapeutics
- Handok Pharmaceuticals
- Hangzhou Chance Pharmaceuticals
- Hangzhou Highlightll Pharmaceutical
- Hangzhou Zhongmei Huadong Pharmaceutical
- HanX Biopharmaceuticals
- Harbour Biomed
- Harmony Biosciences
- Harvard University
- HCW Biologics
- Healios K.K.
- Health Canada
- Healthcare Royalty Partners
- Health Hope Pharma
- Hebrew University of Jerusalem
- Hefei Life Science
- Hefei Tianhui Incubation of Technologies
- Heidelberg Pharma
- HekaBio
- Helmholtz Zentrum Munchen
- Helsinn Therapeutics
- Hemogenyx
- Hemostemix
- HemPup
- Henlius Biotech
- Hepalys Pharma
- Hepion Pharmaceuticals
- Hetero Labs
- HIBio
- HilleVax
- HLS Therapeutics
- Hoffmann La Roche
- Hollister Biosciences
- Hookipa Pharma
- Horizon Therapeutics
- Hoth Therapeutics
- Huadong Medicine
- Humanigen
- Huons
- Hutchmed
- Hyloris Pharmaceuticals
- I-mab
- IASO Biotherapeutics
- Icahn School of Medicine at Mount Sinai
- Ice + Jam
- iCeutica
- Ichnos Glenmark Innovation
- Ichnos Sciences
- IconOVir Bio
- Iconovo
- Icosavax
- IDEAYA Biosciences
- Idera Pharmaceuticals
- Idorsia
- IGM Biosciences
- ImaginAb
- Imbrium Therapeutics
- iMetabolic Biopharma
- Immatics Biotechnologies
- Immedica
- Immugenyx
- ImmuneCyte Life Sciences
- ImmuneOncia Therapeutics
- ImmuneOnco Biopharmaceuticals
- Immune System Regulation
- ImmuNext
- ImmunGene
- Immunic
- ImmunityBio
- ImmunoGen
- Immunome
- Immunomedics
- Immunomic Therapeutics
- ImmunoScape
- Immunovia
- Immutep
- ImmVira
- IMPACT Therapeutics
- Imprimis Pharmaceuticals
- Imugene
- In4Derm
- Incannex Healthcare
- Incuron
- Incyte
- InDex Pharmaceuticals
- Indivior
- Inexia
- InfectoPharm
- Infinity Pharmaceuticals
- InflaRx
- Inhibrx
- Initiator Pharma
- Inmagene Biopharmaceuticals
- InMed Pharmaceuticals
- Innate Pharma
- Innocoll
- Innovate Biopharmaceuticals
- Innovation Pharmaceuticals
- Innovative Cellular Therapeutics
- Innovent Biologics
- Innovet
- Innoviva
- Innoviva Specialty Therapeutics
- INO Therapeutics
- Inovio
- Inovio Pharmaceuticals
- Insilico Medicine
- Insitro
- Insmed Inc
- Inspirna
- Instil Bio
- Intact Therapeutics
- Intarcia Therapeutics
- Intas Pharmaceuticals
- IntelGenx
- Intellia Therapeutics
- Intract Pharma
- Intrexon
- iNtRON Biotechnology
- Invekra
- InveniAI
- Invenra
- Inventiva
- Iolyx Therapeutics
- Ion Channel Innovations
- Ionis Pharmaceuticals
- Iovance Biotherapeutics
- IOVaxis Therapeutics
- Ipsen
- IRLAB
- Iroko Pharmaceuticals
- Ironwood Pharmaceuticals
- Isofol Medical
- Isomorphic Labs
- Itrom Pharmaceutical Group
- Ivantis
- Iveric Bio
- iX Biopharma
- Jacobio Pharmaceuticals
- Jacobus Pharmaceutical
- Jadeite Medicines
- Janssen Biotech
- Janssen Pharmaceuticals
- Janssen Pharmaceutica NV
- Japan Tobacco
- Jazz Pharmaceuticals
- JCR Pharmaceuticals
- Jiangsu Alphamab
- Jiangsu Aosaikang Pharmaceutical
- Jiangsu Chia Tai Tianqing Pharmaceutical
- Jiangsu Hansoh Pharmaceutical
- Jiangsu Hengrui Pharmaceuticals
- Jiangsu NHWA Pharmaceutical
- Jinzhou Ahon Pharma
- Ji Xing Pharmaceuticals
- Johannes Gutenberg University
- John Morley Foods
- Joincare Pharmaceutical
- Jolt Health
- Jounce Therapeutics
- Journey Medical
- Joyo Pharmatech
- JT Pharmaceuticals
- Jubilant Life Sciences
- Jumpcan Pharmaceutical
- Juno Therapeutics
- Junshi Biosciences
- Jupiter Bioventures
- Jupiter Neurosciences
- Jupiter Wellness
- Juventas Therapeutics
- Juyou Biotechnology
- JW Pharmaceutical
- Kadmon Pharmaceuticals
- Kainos Medicines
- Kaken Pharmaceutical
- Kalbe Genexine Biologics
- Kali Therapeutics
- KalVista Pharmaceuticals
- Karuna Therapeutics
- Karveer Meditech
- Karyopharm Therapeutics
- Kashiv BioSciences
- Kastle Therapeutics
- Kazia Therapeutics
- Kelonia Therapeutics
- KemPharm
- Keros Therapeutics
- KeyBioScience
- Keymed Biosciences
- Kezar Life Sciences
- Kiadis Pharma
- Kindred Bio
- Kineta
- Kiniksa Pharmaceuticals
- Kintor
- Kiq
- Kiromic Biopharma
- Kissei Pharmaceutical
- Kite Pharma
- Kitov Pharma
- Klaria
- Klinge Biopharma
- Knighton Foods
- Knight Therapeutics
- Kodiak Sciences
- Kolon Life Science
- Korea Pharma
- Kowa
- Kowa Pharmaceuticals America
- KPM Tech
- Kuhnil Pharmaceuticals
- Kukbo
- Kura Oncology
- KVK-Tech
- Kwangdong Pharmaceutical
- Kwang Dong Pharmaceutical
- Kymera Therapeutics
- Kyn Therapeutics
- Kyowa Hakko Kirin
- Kyverna Therapeutics
- L1 Systems
- Laboratoires Thea
- Laboratories Acbel
- LadRx
- La Jolla Pharmaceutical
- Landos Biopharma
- LaNova Medicines
- Lantheus Holding
- Lantheus Medical Imaging
- Launch Therapeutics
- Lava Therapeutics
- Lee's Pharmaceutical
- Lee Moffitt Cancer Center
- Legend Biotech
- LegoChem Biosciences
- Leiden University
- Leman SKL SA
- LENZ Therapeutics
- LEO Pharma
- Lepu Biopharma
- Les Laboratoires Servier
- Level Brands
- Lexicon Pharmaceuticals
- LG Chem
- LG Life Sciences
- LianBio
- Lifestyle Delivery Systems
- Ligand Pharmaceuticals
- Lighthouse Pharmaceuticals
- LimmaTech Biologics
- Lindy Biosciences
- Lineage Cell Therapeutics
- Link Health
- LIPAC Oncology
- Lipidor
- Lipocine
- Lixte Biotechnology
- Lobesity Pharma
- LogicBio Therapeutics
- Lorna Linda University
- Lotus Pharmaceuticals
- Loxo Oncology
- Lubrizol
- Lucideon
- Lundbeck
- Lung Therapeutics
- Lycia Therapeutics
- Lyell Immunopharma
- Lynk Pharmaceuticals
- Lyra Therapeutics
- Lytix Biopharma
- MaaT Pharma
- MabCare Therapeutics
- Mabwell Bioscience
- Macrogenics
- Madrigal Pharmaceuticals
- Magenta Therapeutics
- MagnaPharm Group
- MainPointe
- Mainz University Medical Centre
- Mallinckrodt Pharmaceuticals
- Mammoth Biosciences
- MannKind Biopharmaceuticals
- Marathon Pharmaceuticals
- Marina Biotech
- Marinus Pharmaceuticals
- Maruho
- Maruishi Pharmaceutical
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- Matrix Biomed
- Mawson Infrastructure
- Mayne Pharma
- Mayo Clinic
- MC2 Therapeutics
- McQuade Center for Strategic Research and Development
- MD Anderson Cancer Center
- Medac
- Medexus Pharmaceuticals
- Mediar Therapeutics
- Medice Arzneimittel Pütter
- Medicines Patent Pool Foundation
- Medicox
- Medicure
- MediGene
- Medigus
- MedImmune
- MedinCell
- Medison Pharma
- Medivir
- MediWound
- Medix
- Medomie Pharma
- MedRhythms
- Medshine Discovery
- MedSteer
- Meiji Seika
- MEI Pharma
- MeiraGTx
- Melinta Therapeutics
- Melior Pharmaceuticals
- Memorial Sloan Kettering Cancer Center
- Memo Therapeutics
- Menarini
- Mercer University
- Merck and Co
- Merck KGaA
- Merck Sharpe & Dohme
- Mereo BioPharma
- Mersana Therapeutics
- Merus
- Mesoblast
- Metacrine
- Metavant
- Methodist Hospital Houston
- Microbio Shanghai
- MiMedx
- Mimi’s Rock
- MiNA Therapeutics
- MindBio Therapeutics
- Mindset Pharma
- Minghui Pharmaceutical
- MiNK Therapeutics
- Miralogx
- Mira Pharmaceuticals
- Mirati Therapeutics
- Miravo Healthcare
- Mirna Therapeutics
- Miromatrix Medical
- Mirum Pharmaceuticals
- Mission Therapeutics
- Mithra Pharmaceuticals
- Mitobridge
- Mitsubishi Tanabe Pharma
- Moderna
- ModeX Therapeutics
- Modis Therapeutics
- Molecular Partners
- Moleculin Biotech
- Molipharma
- Mologen
- Molteni Farmaceutici
- Momenta Pharmaceuticals
- Monash University
- Monopar Therapeutics
- Monte Rosa Therapeutics
- Morgan Stanley
- Morningside Ventures
- Morphic Therapeutic
- MorphoSys
- Mount Sinai Health System
- MultiCell Immunotherapeutics
- Multitude Therapeutics
- Mundipharma
- MycoMedica Life Sciences
- Mylan Laboratories
- Mylan Pharmaceuticals
- MyoKardia
- Myovant Sciences
- Nabriva Therapeutics
- Nanjing Leads Biolabs
- Nanobiotix
- NanoCarrier
- NanoVibronix
- NanoViricides
- NantCell
- NantKwest
- Nantong Jinghua Pharmaceutical
- NantWorks
- Nanyang Technological University
- National Cancer Institute
- National Green Biomed
- National Institute of Allergy and Infectious Diseases
- National Resilience
- National University Hospital
- National University of Singapore
- Navidea Biopharmaceuticals
- Nektar Therapeutics
- Neoleukin Therapeutics
- Neomorph
- Neopharmed Gentili
- Neovacs
- Nestle Health Science
- Neupharma
- Neuraxpharm
- Neuren Pharmaceuticals
- Neurimmune Therapeutics
- Neurizon Therapeutics
- Neuro Bio
- NeuroBo Pharmaceuticals
- Neurocrine Biosciences
- NeuroRx
- NeuroSense Therapeutics
- NeuroTrauma
- NeuroVive Pharmaceutical
- Nevakar
- NewAmsterdam Pharma
- NewG Lab
- NewLeaf Brands
- Newron Pharmaceuticals
- Newsoara Biopharma
- NextCure
- Nextleaf Solutions
- NGM Biopharmaceuticals
- Nicox
- Nicoya
- Nimble Therapeutics
- Nimbus Therapeutics
- Nippon Shinyaku
- NitricGen
- Nkarta Therapeutics
- NLC Pharma
- NLS Pharmaceutics
- Noile-Immune Biotech
- Nona Biosciences
- Norgine
- North Star Holdings
- NorthStar Medical Radioisotopes
- Northwest Biotherapeutics
- Northwestern University
- Notable Labs
- Notch Therapeutics
- Novan
- Novan Therapeutics
- Novartis
- Novavax
- NoveCite
- Novellus Therapeutics
- NovoCodex
- Novocure
- Novo Nordisk
- NRx Pharmaceuticals
- NT Pharma
- Nuance Pharma
- Nucorion
- Numab
- Nunzi Pharmaceutical
- Nurix Therapeutics
- Nuvation Bio
- Nuvo Research
- Nxera Pharma
- NXTGEN
- Nykode Therapeutics
- Oberland Capital
- ObsEva
- Oceanus Bio
- Ocugen
- Ocular Therapeutics
- Oculis
- Oculus Innovative Sciences
- Ocumension Therapeutics
- Ocuphire Pharma
- Odyssey Therapeutics
- Ohio State Innovation Foundation
- OKYO Pharma
- Olema Oncology
- Omega Therapeutics
- Omeros
- OMERS
- OmniAb
- Ona Therapeutics
- OncoArendi Therapeutics
- OncoCyte
- Oncologie
- Oncolytics Biotech
- Onconova Therapeutics
- OncoSec Medical
- OncoX BioPharma
- Onegevity
- Oneness Biotech
- One Way Liver Genomics (OWL)
- ONK Therapeutics
- Ono Pharmaceutical
- Onxeo
- OPKO Health
- Opsis Therapeutics
- Opthea
- OptiBiotix
- Optieum Biotechnologies
- OptiNose
- Opus Genetics
- Oragenics
- Oramed Pharmaceuticals
- Orchard Therapeutics
- Orexia Therapeutics
- Orexigen Therapeutics
- Orexo
- Organon
- Organovo
- Orgenesis
- ORIC Pharmaceuticals
- Orion
- Oruka Therapeutics
- Oscotec
- OSE Immunotherapeutics
- OSI Pharmaceuticals
- OTR Therapeutics
- Otsuka
- Ouro Medicines
- Outpost Medicine
- Ovid Therapeutics
- Oxford BioMedica
- Oxis Biotech
- Oyster Point Pharma
- Paion
- Paladin Labs
- Palatin Technologies
- Palvella Therapeutics
- Pandion Therapeutics
- PANTHERx Specialty Pharmacy
- Paragon Biosciences
- Paratek Pharmaceuticals
- Par Pharmaceutical
- Partner Therapeutics
- Passage Bio
- Patagonia Pharmaceuticals
- Pathos AI
- PDS Biotechnology
- Pediatrix Therapeutics
- PellePharm
- Pepper Bio
- PeptiDream
- Perception Neuroscience
- Pernix Therapeutics
- Pfenex
- Pfizer
- PharmaCyte Biotech
- PharmaEssentia
- PharmAla Biotech
- PharmaMar
- Pharmanovia
- Pharmastrip
- PharmaTher
- Pharming Group
- PhaseBio Pharmaceuticals
- Pheon Therapeutics
- Philochem
- Philogen
- Phosphagenics
- Piedmont Pharmaceuticals
- Pieris Pharmaceuticals
- Pierre Fabre
- Pint Pharma
- Plexium
- Plexxikon
- Pliant Therapeutics
- POINT Biopharma
- Polyphor
- PolyPid
- Polyrizon
- Portola Pharmaceuticals
- Poseida Therapeutics
- Poxel
- Praxis Precision Medicines
- Precigen
- Precision BioSciences
- Prelude Therapeutics
- Presage Biosciences
- Pressure BioSciences
- Prevail Therapeutics
- Prilenia Therapeutics
- PRIMA BioMed
- Primevera Therapeutics
- Principia Biopharma
- PRISM BioLab
- Processa Pharmaceuticals
- Profound Medical
- ProGen Co
- Progenics Pharmaceuticals
- Prokaryotics
- Proliant Health and Biologicals
- Promedico
- Prometheus Biosciences
- ProNAi Therapeutics
- ProQR Therapeutics
- Protagonist Therapeutics
- Protalix BioTherapeutics
- ProteoMediX
- Proteostasis Therapeutics
- Proteovant Therapeutics
- ProtoKinetix
- Provectus Biopharmaceuticals
- Provention Bio
- Providence Therapeutics
- Psyence Therapeutics
- PTC Therapeutics
- PT Etana Biotechnologies
- Pulmatrix
- Puma Biotechnology
- Purdue Pharma
- PureTech Health
- Purnovate
- Pyramid Biosciences
- Pyxis Oncology
- QED Therapeutics
- Qilu Pharmaceutical
- Qualigen
- QuantumCell
- Queensland University of Technology
- Quellis Biosciences
- Quince Therapeutics
- Quoin Pharmaceuticals
- Race Oncology
- Radius Health
- Rafael Pharmaceuticals
- Rain Oncology
- Rani Therapeutics
- Ra Pharmaceuticals
- Rapport Therapeutics
- Rasayana Therapeutics
- Rayner Surgical
- RayzeBio
- Recludix Pharma
- Recordati
- Recursion
- RedHill Biopharma
- Redx Pharma
- Reedy Creek Investments
- Regeneron Pharmaceuticals
- Regenity Biosciences
- Regenxbio
- Regnum
- Regor Therapeutics
- Relay Therapeutics
- Relief Therapeutics
- Relife
- Relmada Therapeutics
- RemeGen
- RenalytixAI
- ReNeuron
- Renovacor
- Repair Biotechnologies
- Repare Therapeutics
- Replicel Life Sciences
- Repligen
- Reprise Biomedical
- Resarci Therapeutics
- Res Nova Bio
- Respira Therapeutics
- Restoration Biologics
- resTORbio
- Resverlogix
- Revance Therapeutics
- ReveraGen BioPharma
- reViral
- Revitope Oncology
- Revive Therapeutics
- Revolution Medicines
- Rexahn Pharmaceuticals
- Rezolute
- Rgene
- Rhinomed
- Rhizen Pharmaceuticals
- Rhythm Pharmaceuticals
- Ribon Therapeutics
- Rigel Pharmaceuticals
- Ripple Therapeutics
- Roche
- Rockefeller University
- Rocket Pharmaceuticals
- RogCon Biosciences
- Roivant Sciences
- Roots Pharmaceutical
- Rosetta Genomics
- Roswell Park Cancer Institute
- ROTOP Pharmaka
- Royalty Pharma
- RQ Biotechnology
- RTW Investments
- Rubius Therapeutics
- Ryvu Therapeutics
- SACCO
- Sagard Healthcare Royalty Partners
- Sage Therapeutics
- Salk Institute
- SAMIL Pharmaceuticals
- Sanara MedTech
- SanBio
- Sandoz
- Sangamo Therapeutics
- Saniona
- Sanofi
- Sanofi-Pasteur
- Sanpellegrino Cosmetics
- SanReno Therapeutics
- Santen Pharmaceutical
- Santhera Pharmaceuticals
- Sanuwave Health
- Sapientia Pharmaceuticals
- Sarepta Therapeutics
- Sato Pharmaceutical
- Satsuma Pharmaceuticals
- Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO)
- Sayre Therapeutics
- Scancell
- Scholar Rock
- Schrodinger
- SciBase
- SciClone Pharmaceuticals
- Scintomics
- SciSparc
- Scopus BioPharma
- Scorpion Therapeutics
- Scribe Therapeutics
- Scripps Research Institute
- Scynexis
- Seagen
- Searchlight Pharma
- Seattle Genetics
- Sebela Pharmaceuticals
- Second Genome
- Secura Bio
- Seelos Therapeutics
- Seer
- Sekris Biomedical
- Selecta Biosciences
- SELLAS Life Sciences Group
- SemaThera
- Senior Paradise
- Senju Pharmaceutical
- Sensory Cloud
- Sentivera
- Sentynl Therapeutics
- Seqirus
- Seres Therapeutics
- Serina Therapeutics
- Sermonix Pharmaceutical
- Serum Institute of India
- Sesen Bio
- SevenScore Pharmaceuticals
- Shandong Luoxin Pharma
- Shanghai Haohai Biological Technology
- Shanghai Pharmaceuticals Holdings
- Shattuck Labs
- Shenzhen BioScien Pharmaceuticals
- Shenzhen Salubris Pharmaceuticals
- Shield Therapeutics
- Shin Nippon Biomedical Laboratories
- Shionogi
- Sierra Oncology
- Sigilon Therapeutics
- Sigyn Therapeutics
- Silence Therapeutics
- Silo Pharma
- Simcere Pharmaceutical
- Simcere Zaiming
- Singlomics Biopharmaceuticals
- Sino Biopharmaceutical
- SinoMab Bioscience
- Sinopharm
- Sinovant Sciences
- Sio Gene Therapies
- Sirion Biotech
- Sirius Therapeutics
- Sirtex Medical
- Sitryx
- SK Biopharmaceuticals
- Skye Bioscience
- SkyePharma
- SmartCella
- Smith & Nephew
- Sol-Gel
- Solarvest BioEnergy
- Solasia Pharma
- Solid Biosciences
- Sona Nanotech
- Sonnet BioTherapeutics
- Sonoma BioTherapeutics
- Sorrento Therapeutics
- Sosei
- Sosei Heptares
- SOTIO
- Spark Therapeutics
- Specialised Therapeutics
- Spectrum Pharmaceuticals
- Spero Therapeutics
- Spring Bank Pharmaceuticals
- SpringWorks Therapeutics
- Sprint Biosciences
- Spruce Biosciences
- STADA Arzneimittel
- Staidson (Beijing) BioPharmaceuticals
- Stanford University
- Starton Therapeutics
- Stealth BioTherapeutics
- Stemline Therapeutics
- StemSynergy
- Stoke Therapeutics
- Strongbridge Biopharma
- Structure Therapeutics
- Sucampo AG
- SUDA Pharmaceuticals
- Sumitomo Dainippon Pharma
- Sumitomo Pharmaceuticals
- Summit Therapeutics
- Sunovion Pharmaceuticals
- Sun Pharmaceutical
- Sunshine Lake Pharma
- Surface Oncology
- Surrozen
- Sutro Biopharma
- Suzhou Connect Biopharmaceuticals
- Suzhou Sinovent Pharmaceuticals
- Swedish Orphan Biovitrum
- Sydys Corporation
- SymBio Pharmaceuticals
- Synaffix
- Syndax Pharmaceuticals
- Synergy Strips
- Synthon
- Syros Pharmaceuticals
- Systec
- T-Cell Protect Hellas
- Tactical Relief
- Taiba
- TaiGen Biotechnology
- Taiho
- Takeda Pharmaceutical
- Takeda Pharmaceuticals U.S.A
- Talaris Therapeutics
- Talem Therapeutics
- Tango Therapeutics
- Target Group
- Targovax
- Tarsus Pharmaceuticals
- Tarveda Therapeutics
- Tasly Pharmaceuticals
- Tauriga Sciences
- Tavros Therapeutics
- Taysha Gene Therapies
- TearLab
- Technion Research and Development Foundation
- Teijin
- Tela Bio
- Telcon RF Pharmaceuticals
- Telix Pharmaceuticals
- Telomir Pharmaceuticals
- Temple University
- Tenacia Biotechnology
- TeneoBio
- Terns Pharmaceuticals
- Terray Therapeutics
- TerSera Therapeutics
- Terumo
- Tesaro
- Tessera Therapeutics
- Tetra Bio-Pharma
- TetraLogic Pharmaceuticals
- Tetraphase Pharmaceuticals
- Teva Pharmaceutical Industries
- TFF Pharmaceuticals
- TG Therapeutics
- Tharimmune
- The Medicines Company
- Therakine
- Theramex
- Theranexus
- TherapeuticsMD
- Therapeutic Solutions International
- Therapharm
- Therapyx
- Theratechnologies
- Theravance
- Theravance Biopharma
- The Regents of the University of California
- Theriva Biologics
- Theseus Pharmaceuticals
- Thorne Research
- TiGenix
- Tilray
- Titan Pharmaceuticals
- TiumBio
- Tizona Therapeutics
- TJ Biopharma
- TLC BioSciences
- Todos Medical
- Tonghua Dongbao Pharma
- TONIX Pharmaceuticals
- Torch Biosciences
- Torii Pharmaceutical
- TRACON Pharmaceuticals
- Transcenta
- Transgene
- Transition Bio
- Translate Bio
- Travere Therapeutics
- TreeFrog Therapeutics
- Trek Therapeutics
- Trevena
- TriSalus Life Sciences
- TScan Therapeutics
- Tubulis
- Tufts Medical Center
- Tufts University
- Turing Pharmaceuticals
- Turning Point Therapeutics
- Turnstone Biologics
- Twist Bioscience
- Tyme Technologies
- Ubix Therapeutics
- Ultragenyx Pharmaceuticals
- Undisclosed Company
- Union Springs Pharmaceuticals
- UNION Therapeutics
- UniQure
- United Therapeutics
- Universal Cells
- University College Dublin
- University of Alberta
- University of Arizona
- University of Basel
- University of California San Francisco
- University of Chicago
- University of Connecticut
- University of Geneva
- University of Heidelberg
- University of Louisville
- University of Massachusetts Medical School
- University of Miami
- University of Missouri
- University of North Carolina
- University of Pennsylvania
- University of Southampton
- University of Texas
- University of Tubingen
- University of Washington
- Unnatural Products
- Uppsalagruppen Medical
- UroGen Pharma
- Urovant Sciences
- Vaccibody
- Vaccinex
- Vactech
- Valeant Pharmaceuticals
- Valneva
- Vanda Pharmaceuticals
- Vasomune Therapeutics
- Vaxart
- VaxEquity
- VAYA Pharma
- VBI Vaccines
- VBL Therapeutics
- Vect-Horus
- Vectura
- Verastem
- Vera Therapeutics
- Veraxa Biotech
- Vericel
- VerImmune
- Verity Pharmaceuticals
- Verrica Pharmaceuticals
- Vertex Pharmaceuticals
- Verve Therapeutics
- Viatris
- VIB
- Vida Concepts
- Vifor-Fresenius Medical Care Renal Pharma
- Vifor Pharma
- ViiV Healthcare
- Vincera Pharma
- Vir Biotechnology
- Viridian Therapeutics
- Vivelix Pharmaceuticals
- Vividion Therapeutics
- Vivus
- Voronoi
- Voyager Therapeutics
- vTv Therapeutics
- Vyera Pharmaceuticals
- Vyluma
- VYNE Therapeutics
- Warp Drive Bio
- WAVE Life Sciences
- Wellcome Trust
- Werewolf Therapeutics
- Whitehawk Therapeutics
- Whitehead Institute
- Wigen Biomedicine
- Wilex
- Windtree Therapeutics
- Winhealth Pharma Group
- World Class Extractions
- WPD Pharmaceuticals
- WUGEN
- WuXi Biologics
- WY Biotech
- X4 Pharmaceuticals
- Xbiome
- Xbrane Biopharma
- Xencor
- Xenetic Biosciences
- Xenon Pharmaceuticals
- XERIS Pharmaceuticals
- Xiamen Amoytop Biotech
- Xilio Therapeutics
- Xlife Sciences
- Xoma
- XPhyto Therapeutics
- Xspray Pharma
- Xuanzhu Biopharma
- XWPharma
- XyloCor Therapeutics
- Xynomic Pharmaceuticals
- Xyphos Biosciences
- Y-Biologics
- Y-mAbs Therapeutics
- Yakult Honsha
- Yale University
- Yarrow Bioscience
- Yissum Research Development
- Yuhan Corporation
- Yungjin Pharmaceutical
- ZAI Laboratory
- Zealand Pharma
- Zenas BioPharma
- Zenith Epigenetics
- Zentalis Pharmaceuticals
- Zenyaku Kogyo
- Zhejiang Conba Pharmaceutical
- Ziopharm Oncology
- Zogenix
- Zydus Cadila
- Zydus Lifesciences
- Zylo Therapeutics
- Zymeworks
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
